1CG trade ideas
Crispr - DNA/Gene editing Technical Analysis
Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in.
The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma.
An appropriate level to exit the trade then, would be below the 50sma.
There also horizontal support as we fill the gap.
Important Note:
Earnings are on February 10th; so be aware of this if you plan to enter the trade.
Opinion
I believe this company is the future of gene editing.
Check out a documentary of the company on Netflix called Human Nature.
*It is more about how Crispr (DNA modification) works, than how the company makes money.
Enjoy your weekend,
dorfmaester
CRISPER_BUYCRSP looking like a BUY on the technicals and a hammer candle stick pattern looks bullish...it did not head and shoulders which would have been a bearish signal to the market...
CRSP - Looking like a great entry point ARK Favorite, looks like a great entry point to me, I hold 8% portfolio at the moment haha
Keep it on your watchlist..! Future of Gene-therapy CRISPR is the future of Medicine without any doubt and its strong trend speaks on its behalf..!
It is always supported around its 50 EMA, and near the bottom of the bullish channel..!
It is also one of the ARK’s favorite..!
Genomics is the future and technicals agree too Easiest play of my life..
Series of higher highs, rising historic volume, nice down move to the prior point of accumulation that took us to our previous All-Time High, Great buy entry. Easy money
CRISPRQuadruple unconfirmed bullish divergence (daily and 4hr) and at a minor support. should break through the trend line again and make its way to that upper resistance/Fibonacci. MAKE SURE MAC D IS IN THE PROCESS OF CROSSING OVER BEFORE ENTERING!!!!!
Great pullback - now the fun beginsCRSP is leader in Genomics and this recent pullback is a perfect buying opportunity for new entrants. If our Elliott wave impulse thesis plays out, the next target could be $290. LONG
CRSP : CRISPR appears to be on SALEIndicators and wave count pointing toward a reversal SOON.
Monitor price action
CRSP short trade updated chartHere is the updated chart on CRSP short trade I posted on January 14th. It's been down 23% since the date it was posted. So far so good. First target was hit today and managed to keep above as I have expected. I expect more downside in days to come. XBI sector can break down anytime too now. Literally one red day will do. My next target is the bottom of the channel colored yellow. Once the selling gets momentum, it will be pretty swift downward move. Definitely can't fall a sleep behind the wheel right now in this market.
Have a good trades everyone,
T.
CRSP Potential ReversalCRSP has had a good initial recovery from the 20day. Looking to play a continuation if it can break the last high. NTLA is also looking like a similar setup, I will be looking to see who leads here.
THE EXCITEMENT AROUND THIS SECTOR IS REALDescription
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Corporate Governance
CRISPR Therapeutics AG’s ISS Governance QualityScore as of December 1, 2020 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 3; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
CRSPCRSP
1D Time Frame
1-2 weeks horizon
Price trending up for the past months respecting the 21ema. We are seeing another pullback approaching the 21ema which also happens to be around the 61.8% fib level. MACD lines are pointing down but over all trend is upwards, histogram suggest weakening bullish momentum (could be a sign of divergence). Stochastics is pointing down heading towards oversold level. Overall, I am bullish on CRSP on the short term.
CRSP 3 Day chart CMF warning signPrice has been going up with the CMF diverging negatively -- could be a warning sign.
20 period CMF even crossed down 0.
Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation.
Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
High probability swing short set up on CRSPHere is my short case on CRSP:
- at the top of trading channel started since Feb 2020
- over bought reading on RSI
- both PPO and RSI shows very clear divergence high
Starting building a position as it hits the top of the channel and scale in as it moves down. Impulsive break of the wedge should move it down to the support at $161. Reaction will be likely, consolidation or a minor bounce. Then, if it gets taken down, then moving down to the bottom of the channel which intersects with $145.80 horizontal support. If that breaks, it's going way lower since $110 and $131 area are pretty thin so the move will be probably pretty swift.
Touching MA. Look for Bullish signs.If we drop below our middle line this is a huge buy. Long term I am very bullish.
